Literature DB >> 1434639

Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67.

A W Hemming1, N L Davis, A Kluftinger, B Robinson, N F Quenville, B Liseman, J LeRiche.   

Abstract

Between January 1989 and August 1991, 62 patients undergoing resection for colorectal adenocarcinoma were assessed in a prospective fashion on the basis of various tumor characteristics that are thought to indicate prognosis. Parameters measured included epidermal growth factor receptor (EGFr) expression, a cell membrane receptor known to be overexpressed in a variety of tumors, Ki-67, a monoclonal antibody marker of cell proliferation, as well as flow cytometry and standard histologic examination. Statistical analysis included chi square with Yates correction when appropriate, Wilcoxon W, and multivariate logistic regression. EGFr positive tumors were associated with worse Dukes' stage (27% of EGFr negative tumors were Dukes' C or D vs. 58% of EGFr positive tumors, P = 0.03), as well as more aneuploid characteristics by flow cytometry (48% EGFr negative = aneuploid vs. 82% EGFr positive = aneuploid, P = 0.01). Lymphatic invasion was more frequent in EGFr positive tumors (P = 0.03). These factors proved to be independent of each other by multivariate analysis. Ki-67 did not correlate with any of the measured parameters and was of extremely limited use in the evaluation of the study population. Multivariate analysis indicated that aneuploid tumors were associated with worse Dukes' stage than diploid tumors. Histologic parameters such as lymphatic and vascular invasion as well as histologic grade are compared to the other parameters involved with prognosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1434639     DOI: 10.1002/jso.2930510304

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  34 in total

1.  High-level mRNA quantification of proliferation marker pKi-67 is correlated with favorable prognosis in colorectal carcinoma.

Authors:  Thomas Ihmann; Jian Liu; Wolfgang Schwabe; Peter Häusler; Detlev Behnke; Hans-Peter Bruch; Rainer Broll; Ute Windhövel; Michael Duchrow
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-21       Impact factor: 4.553

2.  Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.

Authors:  Alenka Ličar; Petra Cerkovnik; Srdjan Novaković
Journal:  Med Oncol       Date:  2010-07-20       Impact factor: 3.064

3.  TNF-α induces upregulation of EGFR expression and signaling in human colonic myofibroblasts.

Authors:  James Yoo; Citlali Ekaterina Rodriguez Perez; Wenxian Nie; Robert A Edwards; James Sinnett-Smith; Enrique Rozengurt
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-02-02       Impact factor: 4.052

4.  IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.

Authors:  Elizabeth L McMichael; Alena Cristina Jaime-Ramirez; Kristan D Guenterberg; Eric Luedke; Lakhvir S Atwal; Amanda R Campbell; Zhiwei Hu; Armika S Tatum; Sri Vidya Kondadasula; Xiaokui Mo; Susheela Tridandapani; Mark Bloomston; E Christopher Ellison; Terence M Williams; Tanios Bekaii-Saab; William E Carson
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

5.  Targeted therapies in colorectal cancer: surgical considerations.

Authors:  Carrie Luu; Amanda K Arrington; Hans F Schoellhammer; Gagandeep Singh; Joseph Kim
Journal:  J Gastrointest Oncol       Date:  2013-09

6.  Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.

Authors:  Katharina Kuester; Andreas Kovar; Christian Lüpfert; Brigitte Brockhaus; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 7.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Authors:  J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari
Journal:  Virchows Arch       Date:  2008-09-18       Impact factor: 4.064

Review 8.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

9.  Association of PYGO2 and EGFR in esophageal squamous cell carcinoma.

Authors:  Meysam Moghbeli; Mohammad Reza Abbaszadegan; Moein Farshchian; Mehdi Montazer; Reza Raeisossadati; Abbas Abdollahi; Mohammad Mahdi Forghanifard
Journal:  Med Oncol       Date:  2013-03-03       Impact factor: 3.064

10.  Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.

Authors:  Kerry J Williams; A Craig Lockhart
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.